NCT05020639View on ClinicalTrials.gov

A Study of TQB3820 in Patients With Hematological Malignancies

PHASE1UnknownINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

August 31, 2021

Primary Completion Date

August 1, 2024

Study Completion Date

December 31, 2024

Conditions
Hematological Malignancies
Interventions
DRUG

TQB3820 tablets

TQB3820 is a novel cereblon-modulating agent.

Trial Locations (2)

30020

RECRUITING

Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin

100020

RECRUITING

Affiliated Beijing Chaoyang Hospital of Capital Medical University, Beijing

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY